Dermatology

DAXI's innovative biochemical composition, replacing HSA with the peptide RTP004, enhances its efficacy, safety, and duration, potentially using less core neurotoxin, positioning it as a groundbreaking botulinum toxin A (BoNTA) for dynamic facial lines treatment.

Dermatologists should be proactive in recommending RZV to all patients over age 50 years, particularly those with a family history of zoster and diseases with altered immune function. Adult patients who are immunocompromised because of their diseases or treatment (e.g., systemic steroids, JAK inhibitors, combination biologic/conventional disease-modifying antirheumatics), should also be encouraged.

Update on Roflumilast cream 0.3% (Zoryve™), Adalimumab-aaty SC use (Yuflyma®), Beremagene geperpavec-svdt topical gene therapy (Vyjuvek™), Molecular imaging device (Orlucent®), Tirbanibulin ointment 1% w/w (Onakta™), Pegunigalsidase alfaiwxj for IV use (Elfabrio®), Autologous cell harvesting device (Recell® System), and Odevixibat capsules/pellets (Bylvay®).

Oral JAK inhibitors are now the first-line treatment for advanced alopecia areata, surpassing topical JAK inhibitors. Baricitinib's FDA approval in 2022 was a significant milestone. More JAK inhibitors are being studied, and additional medications may gain approval soon. JAK inhibitors show promise for alopecia areata with a generally good safety profile, but long-term data is lacking.

Topical ruxolitinib shows promise in various dermatological conditions, including atopic dermatitis, vitiligo, psoriasis, and lichen planus, with a favorable safety profile compared to oral JAK inhibitors. However, its effectiveness in alopecia areata remains inconclusive.

Update on Targeted alkali thermolysis (TAT) technology (Brella™ 3-miniute SweatControl Patch™), Retifanlimab-dlwr for IV infusion (Zynyz™), Spesolimab IV for IV infusion (Spevigo®) and CRISPR-based therapy (NTLA-2002).

The proper and suitable application of antibiotics is crucial in maintaining their effectiveness amidst growing antibiotic resistance. Nevertheless, it is essential for prescribing practitioners to have a heightened understanding of resistance causes and strategies to counteract them.

Chlormethine gel, a topical antineoplastic agent, has shown safety and efficacy in phase II trials and real-world data for treating adult Mycosis Fungoides patients. Despite potential skin-related side effects, chlormethine gel offers a convenient, skin-directed treatment for stage IA and IB MF-CTCL, addressing an unmet need in Canada.

Update on Abrocitinib tablet (Cibinqo®), Lanadelumab-flyo SC injection (Takhzyro®), Berdazimer gel, 10.3% (SB206), Methotrexate oral solution, 2 mg/mL (Jylamvo®), and Anticancer plasmid DNA vaccine (ITI-3000).

Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.

Awareness of the molecular mechanisms of antibiotic resistance among bacteria is necessary to understand the etiology of antibiotic resistance in dermatology at the most basic level.

Update covering: Deucravacitinib tablets (Sotyktu™), mRNA vaccine + pembrolizumab IV combination therapy (mRNA-4157/V940 + Keytruda®), Adalimumab-aacf SC injection (Idacio®), Dupilumab for SC injection (Dupixent®), and Spesolimab IV injection (Spevigo®).

Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need.

Acne scars are a frequent complication that results from damage to the skin during the healing process of lesions, with studies indicating that 50% of those suffering from acne may develop scars.

Update covering: Deucravacitinib tablets (Sotyktu™), DaxibotulinumtoxinA-lanm IM injection (Daxxify™), Dupilumab for SC injection (Dupixent®), Spesolimab-sbzo IV injection (Spevigo®) and Selumetinib capsules (Koselugo™).

Results from multiple studies have shown promising response rates, and extracorporeal photopheresis has an overall excellent safety profile with very few adverse events reported.

Toxic epidermal necrolysis (TEN) is an immune-mediated, severe cutaneous adverse drug reaction characterized by epidermal detachment affecting greater than 30% body surface area.

Update covering: Roflumilast cream 0.3% (Zoryve™), Ruxolitinib cream 1.5% (Opzelura™), HA-based dermal filler (Juvéderm® Volux™ XC), Abrocitinib tablets (Cinbinqo®), LetibotulinumtoxinA for injection (Letybo®), Berotralstat capsules (Orladeyo®), Mogamulizumab IV infusion (Poteligeo®), and Avacopan capsules (Tavneos®).

Tazarotene 0.045% lotion is a novel formulation which utilizes polymeric emulsion technology to improve tolerability and epidermal penetration. Despite the lower concentration of tazarotene in the lotion formulation, which likely also contributes to improved tolerability, tazarotene 0.045% lotion is at least as effective as tazarotene 0.1% cream.

Tirbanibulin effectively and completely cleared AK lesions with a 5-day application period while demonstrating a favorable safety profile, mild AEs, improved tolerability, and long-term results, making it a promising field therapy for AKs.

Update covering: Benzoyl peroxide 5% cream, Isotretinoin ointment, Tapinarof 1% cream, Baricitinib tablets, and Dupilumab for SC injection.

A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.

Sarecycline is a novel antibiotic that has shown significant promise in acne treatment due to its narrow-spectrum activity and weight-based dosing.

This update covers Nivolumab + Relatlimab-rmbw for IV use - Opdualag™ (Bristol-Myers Squibb), Sirolimus topical gel 0.2% - Hyftor™ (Nobelpharma America), Oral epinephrine - AQST-109 (Aquestive Therapeutics), and Bimekizumab for SC use - Bimzelx® (UCB Canada Inc.).

Emerging molecular experimental and clinical data suggests that CXCR4 may play an important role in other skin and systemic diseases including mycosis fungoides/Sézary syndrome, neurofibromatosis type 1 tumors, allergic reactions, Waldenström macroglobulinemia, melanoma, non-melanoma skin cancers and other solid tumors.

The benefits of transitioning from Cal/BD ointment or gel to aerosol foam formulation in this Canadian patient population were similar to those reported in clinical studies and were seen consistently among patients with a range of treatment priorities and with differing history of psoriasis severity and treatment history.

This update covers Adalimumab biosimilar - Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar - Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet - Cibinqo® (Pfizer), Upadacitinib tablet - Rinvoq® (AbbVie), Risankizumab-rzaa SC injection - Skyrizi® (AbbVie), and HA-based dermal filler - Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).

Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.

Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.

Drug update covering: Adalimumab-adbm for SC use - Cyltezo®, Tralokinumab for SC use - Adtralza® (in Canada), Tralokinumab-ldrm for SC use - Adbry™ (in US), Melanoma vaccine for IV use - BNT111, Adalimumab-aqvh for SC use - Yusimry™, and more...

This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.

A novel fixed combination lotion containing the super-potent corticosteroid halobetasol propionate 0.01% and retinoid tazarotene 0.045% (Duobrii™) has recently been introduced and indicated for the treatment of moderate to severe plaque psoriasis in adults.

Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.

The update covers Difelikefalin for IV use - Korsuva™ (Vifor Pharma, Cara Therapeutics), Topical MEK inhibitor - NFX-179 (NFlextion Therapeutics), Maralixibat oral solution - Livmarli™ (Mirum Pharmaceuticals), Ruxolitinib cream 1.5% - Opzelura™ (Incyte), Ruxolitinib tablets - Jakafi® (Incyte), and Avacopan capsules - Tavneos™ (ChemoCentryx).

Consumers of personal care products must be made aware of the potential pitfalls that arise from current labeling practices and regulations. For example, terms such as “hypoallergenic“, “sensitive skin“, and ...

This article is a general overview of hair removal practices, which have evolved from utilizing waxes and blades, to advanced lasers and electrolysis, with further advancements still being studied

The update covers: Tazarotene lotion, 0.045% - Arazlo™ (Bausch Health), Anifrolumab-fnia IV use - Saphnelo™ (AstraZeneca), Immune globulin intravenous (human) 10% - Octagam® 10% (Octapharma), Odevixibat capsule - Bylvay™ (Albireo Pharma) and other treatments

This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.

Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.

The update covers: Secukinumab for SC use - Cosentyx® (Novartis), Brincidofovir tablets and oral suspension - Tembexa® (Chimerix), Plasminogen, humantvmh - Ryplazim® (Liminal BioSciences), Halobetasol propionate lotion 0.01% w/w - Bryhali™ (Bausch Health), and Nomacopan for SC use (Akari Therapeutics).